COVID 19 Clinical Trial
Official title:
Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia Multicentric Randomized Comparative Study
Evaluation of the efficacy and safety of Treatments for Patients Hospitalized for COVID-19 Infection without signs of acute respiratory failure, in Tunisia Multicentric Randomized Comparative Study
Arm 1:
- Hydroxychloroquine (HCQ): 600 mg on the 1st day as a starting dose then 200 mg * 2 /D
for 9 days
- Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days
- Usual standard treatment
Arm 2:
- HCQ: 600 mg on the 1st day as a starting dose then 200 mg * 2 / D for 9 days
- Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days
- Zinc: 220 mg per day for 10 days
- Usual standard treatment
Arm 3:
- Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days
- Doxycycline: 200 mg per day for 10 days.
- Usual standard treatment
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04333732 -
CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
|
Phase 3 | |
| Completed |
NCT04357457 -
Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia
|
Phase 3 | |
| Terminated |
NCT04435795 -
Inhaled Ciclesonide for Outpatients With COVID19
|
Phase 2/Phase 3 | |
| Completed |
NCT04357444 -
Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19
|
Phase 2 | |
| Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
| Not yet recruiting |
NCT05052320 -
Audiological Assessment of Recovered Covid 19 Subjects.
|
||
| Withdrawn |
NCT04426344 -
Core Warming of COVID-19 Patients
|
N/A | |
| Recruiting |
NCT05595031 -
Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO)
|
||
| Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
| Terminated |
NCT04401410 -
Anti-SARS Cov-2 T Cell Infusions for COVID 19
|
Phase 1 | |
| Completed |
NCT04445337 -
Stellate Ganglion Blockade in COVID-19 Positive Patients
|
N/A | |
| Active, not recruiting |
NCT04374487 -
Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications
|
Phase 2 | |
| Completed |
NCT04403243 -
COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19
|
Phase 2 | |
| Completed |
NCT04375644 -
Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT)
|
||
| Completed |
NCT04394078 -
Impact of COVID-19 Pandemic on Depression and Quality of Life
|
||
| Recruiting |
NCT04407923 -
Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
|
||
| Completed |
NCT04426305 -
Community Health Workers Against COVID19
|
N/A | |
| Withdrawn |
NCT04519411 -
Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure
|
N/A | |
| Recruiting |
NCT04492514 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation
|
Phase 2 | |
| Completed |
NCT04399980 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
|
Phase 2 |